









8. Chen JJ, Applebaum DS, Sun GS, et al. Atopic keratoconjunctivitis: a review. *J Am Acad Dermatol.* 2014;70:569-575.
9. Andreanos KD, Hashemi K, Petrelli M, et al. Keratoconus treatment algorithm. *Ophthalmol Ther.* 2017;6:245-262.
10. Rahi A, Davies P, Ruben M, et al. Keratoconus and coexisting atopic disease. *Br J Ophthalmol.* 1977;61:761-764.
11. Gasset AR, Hinson WA, Frias JL. Keratoconus and atopic diseases. *Ann Ophthalmol.* 1978;10:991-994.
12. Bawazeer AM, Hodge WG, Lorimer B. Atopy and keratoconus: a multivariate analysis. *Br J Ophthalmol.* 2000;84:834-836.
13. Galvis V, Sherwin T, Tello A, et al. Keratoconus: an inflammatory disorder? *Eye (Lond).* 2015;29:843-859.
14. Clark AF, Wordinger RJ. The role of steroids in outflow resistance. *Exp Eye Res.* 2009;88:752-759.
15. Daniel BS, Orchard D. Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. *Australas J Dermatol.* 2015;56:164-169.
16. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. *Clin Exp Ophthalmol.* 2004;32:224-226.
17. Aggarwal RK, Potamitis T, Chong NH, et al. Extensive visual loss with topical facial steroids. *Eye (Lond).* 1993;7(pt 5):664-666.
18. Mandapati JS, Metta AK. Intraocular pressure variation in patients on long-term corticosteroids. *Indian Dermatol Online J.* 2011;2:67-69.
19. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. *Curr Opin Ophthalmol.* 2006;17:163-167.
20. Tamagawa-Mineoka R, Yasuoka N, Ueta M, et al. Influence of topical steroids on intraocular pressure in patients with atopic dermatitis. *Allergol Int.* 2018;67:388-391.
21. Bercovitch L. Screening for ocular complications in atopic dermatitis. *Arch Dermatol.* 2011;147:588-589.
22. Abramovits W, Hung P, Tong KB. Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis. *Am J Clin Dermatol.* 2006;7:213-222.
23. Takakuwa K, Hamanaka T, Mori K, et al. Atopic glaucoma: clinical and pathophysiological analysis. *J Glaucoma.* 2015;24:662-668.
24. Haec IM, Rouwen TJ, Timmer-de Mik L, et al. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. *J Am Acad Dermatol.* 2011;64:275-281.
25. Amemiya T, Matsuda H, Uehara M. Ocular findings in atopic dermatitis with special reference to the clinical features of atopic cataract. *Ophthalmologica.* 1980;180:129-132.
26. Tatham A. Atopic dermatitis, cutaneous steroids and cataracts in children: two case reports. *J Med Case Rep.* 2008;2:124.
27. Chew M, Chiang PP, Zheng Y, et al. The impact of cataract, cataract types, and cataract grades on vision-specific functioning using Rasch analysis. *Am J Ophthalmol.* 2012;154:39-38.
28. Nagaki Y, Hayasaka S, Kadoi S. Cataract progression in patients with atopic dermatitis. *J Cataract Refract Surg.* 1999;25:96-99.
29. Kaye LD, Kalenak JW, Price RL, et al. Ocular implications of long-term prednisone therapy in children. *J Pediatr Ophthalmol Strabismus.* 1993;30:142-144.
30. Matsuo T, Saito H, Matsuo N. Cataract and aqueous flare levels in patients with atopic dermatitis. *Am J Ophthalmol.* 1997;124:36-39.
31. Namazi MR, Handjani F, Amirahmadi M. Increased oxidative activity from hydrogen peroxide may be the cause of the predisposition to cataracts among patients with atopic dermatitis. *Med Hypotheses.* 2006;66:863-864.
32. James ER. The etiology of steroid cataract. *J Ocul Pharmacol Ther.* 2007;23:403-420.
33. Lambert SR, Teng JMC. Assessing whether the cataracts associated with atopic dermatitis are associated with steroids or inflammatory factors. *JAMA Ophthalmol.* 2018;136:918-919.
34. Sasoh M, Mizutani H, Matsubara H, et al. Incidence of retinal detachment associated with atopic dermatitis in Japan: review of cases from 1992 to 2011. *Clin Ophthalmol.* 2015;9:1129-1134.
35. Yoneda K, Okamoto H, Wada Y, et al. Atopic retinal detachment. report of four cases and a review of the literature. *Br J Dermatol.* 1995;133:586-591.
36. Gnana Jothi V, McGimpsey S, Sharkey JA, et al. Retinal detachment repair and cataract surgery in patients with atopic dermatitis. *Eye (Lond).* 2017;31:1296-1301.
37. Oka C, Ideta H, Nagasaki H, et al. Retinal detachment with atopic dermatitis similar to traumatic retinal detachment. *Ophthalmology.* 1994;101:1050-1054.
38. Prabirputaloo T, Margolis TP, Lietman TM, et al. Atopic disease and herpes simplex eye disease: a population-based case-control study. *Am J Ophthalmol.* 2006;142:745-749.
39. Borjes D, Gonzales JA, Tham VM, et al. Association between atopy and Herpes eye disease: results from the Pacific Ocular Inflammation Study. *Am J Ophthalmol.* 2014;132:326-331.
40. Rezende RA, Hammersmith K, Bisol T, et al. Comparative study of ocular herpes simplex virus in patients with and without self-reported atopy. *Am J Ophthalmol.* 2006;141:1120-1125.
41. Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. *J Allergy Clin Immunol Pract.* 2018;6:1778-1780.e1.
42. Ivert LU, Wahlgren CF, Ivert L, et al. Eye complications during dupilumab treatment for severe atopic dermatitis. *Acta Derm Venereol.* 2019;99:375-378.
43. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials [published online March 9, 2019]. *Br J Dermatol.* doi:10.1111/bjd.17869.
44. Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. *Br J Dermatol.* 2019;180:1248-1249.
45. Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report. *JAAD Case Rep.* 2019;5:34-36.